The Top 5 Biosimilar Articles for the Week of May 16

Video

Here are the top 5 biosimilar articles for the week of May 16, 2022.

Hi, I’m Skylar Jeremias for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.

Here are the top 5 biosimilar articles for the week of May 16, 2022.

Number 5: Posters from the Academy of Managed Care Pharmacy (AMCP)’s annual meeting examined the real-world patterns of biosimilar utilization and the impact of products that have been reclassified as biologics on Medicaid spending.

Number 4: A new bill that would amend the Federal Food, Drug, and Cosmetic Act aims to expand FDA user fee programs for prescription drugs and medical devices, including biosimilars and generics.

Number 3: Biocon’s total revenue for the fourth quarter of the 2022 fiscal year was up 21% from the same period in the prior year, largely due to significant growth in sales for the company’s biosimilar and generic drugs.

Number 2: The United Kingdom has approved Teva Pharmaceutical’s biosimilar (Ongavia), which references Lucentis (ranibizumab), for the treatment of several ophthalmic conditions.

Number 1: In a pharmacokinetic study, Alvotech’s ustekinumab biosimilar referencing Stelara was shown to have comparable safety and efficacy to the reference product, according to the company’s preliminary results.

To read all of these articles and more, visit centerforbiosimilars.com.

Related Videos
Here are the top 5 biosimilar articles for the week of September 11, 2023.
Fran Gregory, PharmD, MBA
Here are the top 5 biosimilar articles for the week of August 28, 2023.
Here are the top 5 biosimilar articles for the week of August 28, 2023.
Fran Gregory, PharmD, MBA
Here are the top 5 biosimilar articles for the week of August 21, 2023.
Here are the top 5 biosimilar articles for the week of August 14, 2023.
Related Content
© 2023 MJH Life Sciences

All rights reserved.